Company intelligence / Profile preview

CinnaGen

Ownership: Private
Employees: ~2250
Development stage: Commercial

Overview

CinnaGen has commercialized over a dozen biosimilars across neurology/MS, oncology/hematology, endocrinology/growth disorders and autoimmune disease. It was the first MENA company to receive EMA GMP certification for its full-cycle biologics plant. The company continues to expand into new markets with ongoing clinical trials of additional biosimilars—including European studies—and has developed a recombinant COVID‑19 vaccine with international partners.

Therapeutic areas: RheumatologyOphthalmologyEndocrinologyImmunologyWomen's HealthOncologyRare DiseasesNeurologyInfectious Diseases
Modalities: BiosimilarsMonoclonal antibodies (mAbs)Recombinant proteinsTherapeutic enzymesSynthetic peptidesVaccines (e.g., recombinant COVID vaccine)Small molecules (limited; focus on biologics)
Industry: Biotech

Drug pipeline

8 assets

SpikoGen

7 more assets in the full pipeline.

Request access →

Partnerships

licensing agreements with Fraunhofer Institute Germany for CinnoVexcollaboration with Vaxine Australia on SpikoGen COVID vaccinevarious academic/research collaborations

Beyond the preview

Go deeper on CinnaGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CinnaGen.

Explore the full profile